Gilead Licensing Deal Expands Remdesivir Access, Capacity
Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
You may also be interested in...
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral take multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.